Development of an inactivated vaccine candidate for SARS-CoV-2

Cited by (1,438)

Items 201–300 of 1,438

1. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers
   Ayşen Bayram, Hadiye Demirbakan, Pınar Günel Karadeniz, Merve Erdoğan, İpek Koçer · 2021 · Journal of Medical Virology
2. COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
   Ramandeep Singh, Alisha Kang, Xiang‐Qian Luo, Mangalakumari Jeyanathan, Amy E. Gillgrass, Sam Afkhami, Zhou Xing · 2021 · The FASEB Journal
3. Neutralizing Antibody Responses in COVID-19 Convalescent Sera
   Lee, William T, Girardin, Roxanne C, Dupuis, Alan P, Kulas, Karen E, Payne, Anne F, Wong, Susan J, Arinsburg, Suzanne, Nguyen, Freddy T, Mendu, Damodara Rao, Firpo-Betancourt, Adolfo et al. · 2021 · The Journal of Infectious Diseases
4. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
   Debra Van Egeren, Alexander Novokhodko, Madison Stoddard, Uyen Tran, Bruce R. Zetter, Michael S. Rogers, Bradley L. Pentelute, Jonathan M. Carlson, Mark S. Hixon, Diane Joseph‐McCarthy et al. · 2021 · PLoS ONE
5. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly
   Emire Seyahi, Guldaran Bakhdiyarli, Mert Öztaş, Mert Ahmet Kuşkucu, Yeşim Tok, Necdet Süt, Guzin Ozcifci, Ali Özçağlayan, İ̇lker İnanç Balkan, Neşe Saltoğlu et al. · 2021 · Rheumatology International
6. COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
   Mohammad Sultan Khuroo, Mohammad Sultan Khuroo, Mehnaaz S. Khuroo, Ahmad A. Sofi, Naira S. Khuroo · 2020 · Journal of Clinical and Experimental Hepatology
7. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
   Wenjun Wang, Baoying Huang, Yanping Zhu, Wenjie Tan, Mingzhao Zhu · 2021 · Cellular and Molecular Immunology
8. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
   Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, Dipankar Das, Narasimha Reddy Molugu, Sai D. Prasad, Srinivas V. Kannappa, Krishna M. Ella, Rajaram Ravikrishnan, Amit Awasthi et al. · 2021 · iScience
9. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine
   Dong An, Kun Li, Dawne K. Rowe, María Cristina Gingerich, Emily Fate Griffin, Ashley C. Beavis, Scott K. Johnson, Ian Padykula, Cheryl A. Jones, Kelsey Briggs et al. · 2021 · Science Advances
10. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein
    Ahmed Rakib, Saad Ahmed Sami, Nusrat Jahan Mimi et al. · 2020 · Computers in Biology and Medicine
11. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Saborni Chakraborty, Vamsee V. A. Mallajosyula, Cristina M. Tato, Gene S. Tan, Taia T. Wang · 2021 · Advanced Drug Delivery Reviews
12. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
    Nanda Kishore Routhu, Narayanaiah Cheedarla, Sailaja Gangadhara, Venkata Satish Bollimpelli, Arun Kumar Boddapati, Ayalnesh Shiferaw, Sheikh Abdul Rahman, Anusmita Sahoo, Venkata Viswanadh Edara, Lilin Lai et al. · 2021 · Immunity
13. The role of type I interferon in the treatment of COVID‐19
    Fatemeh Sodeifian, Mahsa Nikfarjam, Naghmeh Kian, Kawthar Mohamed, Nima Rezaei · 2021 · Journal of Medical Virology
14. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
    Tania Gupta, Shishir Kumar Gupta · 2020 · International Immunopharmacology
15. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
    John P. Moore, Per Johan Klasse · 2020 · Journal of Virology
16. Developing a low-cost and accessible COVID-19 vaccine for global health
    Peter Jay Hotez, María Elena Bottazzi · 2020 · PLoS neglected tropical diseases
17. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies
    Praveen Mathews Varghese, Anthony George Tsolaki, Hadida Yasmin, Abhishek Shastri, Janez Ferluga, Manu Vatish, Taruna Madan, Uday Kishore · 2020 · Immunobiology
18. Targets and strategies for vaccine development against SARS-CoV-2
    Jonaid Ahmad Malik, Almas Hanif Mulla, Tahmeena Farooqi, Faheem Hyder Pottoo, Sirajudheen Anwar, Kannan R. R. Rengasamy · 2021 · Biomedicine & Pharmacotherapy
19. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
    Bin Zheng, Wenchang Peng, Mingming Guo, Mengqian Huang, Yuxuan Gu, Tao Wang, Guangjian Ni, Dong Ming · 2021 · Chemical Engineering Journal
20. The COVID-19 Vaccines: Recent Development, Challenges and Prospects
    Yuxin Yan, Yoong Xin Pang, Zhuoyi Lyu, Ruiqi Wang, Xinyun Wu, Chong You, Haitao Zhao, Sivakumar Manickam, Edward Henry Lester, Tao Wu et al. · 2021 · Vaccines
21. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters
    Yangtao Wu, Xiaofen Huang, Lunzhi Yuan, Shaojuan Wang, Yali Zhang, Hualong Xiong, Rirong Chen, Jian Ma, Ruoyao Qi, Meifeng Nie et al. · 2021 · Science Translational Medicine
22. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
    Kalnin, Kirill V., Plitnik, Timothy, Kishko, Michael, Zhang, Jinrong, Zhang, Donghui, Beauvais, Adrien, Anosova, Natalie G., Tibbitts, Tim, DiNapoli, Josh, Ulinski, Gregory et al. · 2021 · npj Vaccines
23. COVID-19 vaccines: neutralizing antibodies and the alum advantage
    Peter Jay Hotez, David Brian Corry, Ulrich Strych, María Elena Bottazzi · 2020 · Nature reviews. Immunology
24. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries
    Ali J. Marian · 2020 · Cardiovascular Pathology
25. Structure-based development of human antibody cocktails against SARS-CoV-2
    Nan Wang, Yao Sun, Rui Feng, Yuxi Wang, Yan Guo, Li Zhang, Yong‐Qiang Deng, Lei Wang, Zhen Cui, Lei Cao et al. · 2020 · Cell Research
26. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
    Cole J. Batty, Mark T. Heise, Eric M. Bachelder, Kristy M. Ainslie · 2020 · Advanced Drug Delivery Reviews
27. Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
    Qinheng Zheng, Ziyang Zhang, Keelan Z. Guiley, Kevan M. Shokat · 2024 · Nature Chemical Biology
28. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
    P. Jin, Jingxin Li, H. Pan, Yan-Fei Wu, F. Zhu · 2021 · Signal Transduction and Targeted Therapy
29. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
    Shiyu Sun, Yueqi Cai, Tian‐Zhang Song, Pu Yang, Lin Cheng, Hairong Xu, Jing Sun, Chaoyang Meng, Yifan Lin, Haibin Huang et al. · 2021 · Cell Research
30. COVID-19 Vaccines: An Overview of Different Platforms
    Dmitry Anatolievich Kudlay, Andrey А. Svistunov · 2022 · Bioengineering
31. Status Report on COVID-19 Vaccines Development
    Arun Kumar, William E. Dowling, Raúl Gómez Román, Amol B. Chaudhari, Céline Gurry, Tung Thanh Le, Stig Tollefson, Carolyn E. Clark, Valentina Bernasconi, Paul A. Kristiansen · 2021 · Current Infectious Disease Reports
32. An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
    Saeed Khoshnood, Maniya Arshadi, Sousan Akrami, Maryam Koupaei, Hossein Ghahramanpour, Aref Shariati, Nourkhoda Sadeghifard, Mohsen Heidary · 2022 · Journal of Clinical Laboratory Analysis
33. Immunization against Zika by entrapping live virus in a subcutaneous self-adjuvanting hydrogel
    Haibin Hao, Shipo Wu, Jiake Lin, Zitong Zheng, Yuemin Zhou, Ying Zhang, Qiang Guo, Fengchao Tian, Mengsu Zhao, Yi Chen et al. · 2023 · Nature Biomedical Engineering
34. Animal models for SARS‐CoV‐2 research: A comprehensive literature review
    Kabita Pandey, Arpan Acharya, Mahesh Mohan, Caroline L. Ng, St Patrick Reid, Siddappa N. Byrareddy · 2020 · Transboundary and Emerging Diseases
35. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
    Lairun Jin, Zhuopei Li, Xiaoyin Zhang, Jingxin Li, Fengcai Zhu · 2022 · Human Vaccines & Immunotherapeutics
36. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza
    Linlin Bao, Wei Deng, Feifei Qi et al. · 2021 · Signal Transduction and Targeted Therapy
37. A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
    María Pino, Talha Abid, Susan Pereira Ribeiro, Venkata Viswanadh Edara, Katharine A. Floyd, Justin C. Smith, Muhammad Bilal Latif, Gabriela Pacheco Sánchez, Debashis Dutta, Shelly Wang et al. · 2021 · Science Immunology
38. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
    L. Kozlovskaya, A. Piniaeva, G. Ignatyev, I. Gordeychuk, V. Volok, Y. V. Rogova, A. Shishova, A. Kovpak, Y. Ivin, L. Antonova et al. · 2021 · Emerging Microbes and Infections
39. Advances in the design and development of SARS-CoV-2 vaccines
    Xue‐Liang Peng, Ji‐Si‐Yu Cheng, Hai‐Lun Gong, Meng-Di Yuan, Xiaohong Zhao, Zibiao Li, Dai‐Xu Wei · 2021 · Military Medical Research
40. Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies
    Arun Samidurai, Anindita Das · 2020 · International Journal of Molecular Sciences
41. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
    Qingrui Huang, Kai Ji, Siyu Tian, Fengze Wang, Baoying Huang, Zhou Tong, Shuguang Tan, Junfeng Hao, Qihui Wang, Wenjie Tan et al. · 2021 · Nature Communications
42. Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These?
    Ilka Engelmann, Enagnon Kazali Alidjinou, Judith Ogiez, Quentin Pagneux, Sana Miloudi, Ilyes Benhalima, Mahdi Ouafi, Famara Sané, Didier Hober, Alain Roussel et al. · 2021 · ACS Omega
43. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines
    Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, Vinícius Couto Pires, Luis Alberto Breda Mascarenhas, Leone Peter Correia da Silva Andrade, Marcelo Albano Moret, Roberto José da Silva Badaró · 2022 · Vaccines
44. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
    Lim, Joey Ming Er, Hang, Shou Kit, Hariharaputran, Smrithi, Chia, Adeline, Tan, Nicole, Lee, Eng Sing, Chng, Edwin, Lim, Poh Lian, Young, Barnaby E., Lye, David Chien et al. · 2022 · Cell Reports Medicine
45. Nanomedicine as A Promising Approach For Diagnosis, Treatment and Prophylaxis Against COVID-19
    Noura Hassan Abd Ellah, Sheryhan F. Gad, Khalid Muhammad, Gaber El‐Saber Batiha, ‏Helal F. Hetta · 2020 · Nanomedicine
46. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
    Cillian Gartlan, Tom Tipton, Francisco Javier Salguero, Quentin James Sattentau, Andrew R. GORRINGE, Miles W. Carroll · 2022 · Frontiers in Immunology
47. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
    Ebenezer Tumban · 2020 · Viruses
48. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
    Haya Altawalah · 2021 · Vaccines
49. Progress and prospects on vaccine development against monkeypox infection
    Mohamed Jamal Saadh, Tahmineh Ghadimkhani, Narges Soltani, Arian Abbassioun, Renzon Daniel Cosme Pecho, Ali taha, Tareq Jwad Kazem, Saman Yasamineh, Omid Gholizadeh · 2023 · Microbial Pathogenesis
50. Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations
    Sivakumar S. Moni, Siddig İbrahim Abdelwahab, Aamena Jabeen, Mohamed Eltaib Elmobark, Duaa Othman Aqaili, Gassem Gohal, Bassem Oraibi, Abdulla Farasani, Ahmed Ali Jerah, Mahdi M. Alnajai et al. · 2023 · Vaccines
51. Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity
    Maximilian Koblischke, M. Traugott, Iris Medits, Felicia S. Spitzer, A. Zoufaly, Lukas Weseslindtner, Cara Simonitsch, T. Seitz, W. Hoepler, E. Puchhammer-Stöckl et al. · 2020 · Frontiers in Medicine
52. Graphene Sheets with Defined Dual Functionalities for the Strong SARS‐CoV‐2 Interactions
    Ievgen S. Donskyi, Chuanxiong Nie, Kai Ludwig, Jakob Trimpert, Rameez Ahmed, Elisa Quaas, Katharina Achazi, Jörg Radnik, Mohsen Adeli, Rainer Haag et al. · 2021 · Small
53. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies
    Qi Xiang, Linhao Li, Jie Wu, Miao Tian, Yang Fu · 2022 · Microbiological Research
54. Engineering Antiviral Vaccines
    Xingwu Zhou, Xing Jiang, Moyuan Qu, George E. Aninwene, Vadim Jucaud, James Jaehyun Moon, Zhen Gu, Wujin Sun, Ali Khademhosseini · 2020 · ACS Nano
55. Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID‐19): Are they similar?
    Saverio Paltrinieri, Alessia Giordano, Angelica Stranieri, Stefania Lauzi · 2020 · Transboundary and Emerging Diseases
56. The find of COVID-19 vaccine: Challenges and opportunities
    Marwan ElBagoury, Mahmoud M. Tolba, Hebatallah Ahmed Nasser, Abdul Jabbar, Ahmed M. Elagouz, Yahia Aktham, Amy Hutchinson · 2020 · Journal of Infection and Public Health
57. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
    Li Zhang, Lei Cao, Xingsu Gao, Binyang Zheng, Yong‐Qiang Deng, Jingxin Li, Rui Feng, Qian Bian, Xiling Guo, Nan Wang et al. · 2021 · National Science Review
58. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model
    Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa et al. · 2021 · iScience
59. An overview on the treatments and prevention against COVID-19
    Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, Fatemeh Beiraghdar, Abolfazl Akbarzadeh, Vahideh Tarhriz, Hassan Mellatyar · 2023 · Virology Journal
60. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
    Zang, Jinkai, Gu, Chenjian, Zhou, Bingjie, Zhang, Chao, Yang, Yong, Xu, Shiqi, Bai, Lulu, Zhang, Rong, Deng, Qiang, Yuan, Zhenghong et al. · 2020 · Cell Discovery
61. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
    Y. Sui, Jianping Li, Roushu Zhang, S. Prabhu, H. Andersen, D. Venzon, Anthony Cook, Renita Brown, Elyse Teow, Jason Velasco et al. · 2021 · JCI Insight
62. Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
    Zhan Zhang, Qi Shen, Haocai Chang · 2022 · Frontiers in Immunology
63. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
    Nasamon Wanlapakorn, Nungruthai Suntronwong, Harit Phowatthanasathian, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Chompoonut Auphimai, Donchida Srimuan, Thaksaporn Thatsanatorn, Suvichada Assawakosri et al. · 2022 · Human Vaccines & Immunotherapeutics
64. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates
    Tingting Li, Qingbing Zheng, Hai Jing Yu, Dinghui Wu, Wenhui Xue, Hualong Xiong, Xiaofen Huang, Meifeng Nie, Mingxi Yue, Rui Rong et al. · 2020 · Emerging Microbes & Infections
65. Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection
    Sang Heui Seo, Yunyueng Jang · 2020 · Vaccines
66. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · Science Translational Medicine
67. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding
    Jakob Trimpert, Kristina Dietert, Theresa C. Firsching, Nadine Ebert, Tran Thi Nhu Thao, Daria Vladimirova, Susanne Kaufer, Fabien Labroussaa, Azza Abdelgawad, Andelé M. Conradie et al. · 2021 · Cell Reports
68. Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets
    Jeong Seok Lee, June‐Young Koh, Kijong Yi, Young‐Il Kim, Su‐Jin Park, Se‐Mi Kim, Se-Mi Kim, Sung Ho Park, Young Seok Ju, Young Ki Choi et al. · 2021 · Nature Communications
69. Resolving adjuvant mode of action to enhance vaccine efficacy
    Joanna L. Turley, Ed C. Lavelle · 2022 · Current Opinion in Immunology
70. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
    He, Xuan, Chandrashekar, Abishek, Zahn, Roland, Wegmann, Frank, Yu, Jingyou, Mercado, Noe B., McMahan, Katherine, Martinot, Amanda J., Piedra-Mora, Cesar, Beecy, Sidney et al. · 2021 · Cell
71. Exploring lectin–glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses
    Luís Cláudio Nascimento da Silva, Juliana Silva Pereira Mendonça, Weslley Felix de Oliveira, Karla Lílian Rodrigues Batista, Adrielle Zagmignan, Isabelle F. T. Viana, Maria Tereza dos Santos Correia · 2020 · Glycobiology
72. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
73. Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation
    Joel D. Allen, Himanshi Chawla, Firdaus Samsudin, Lorena Zuzic, Aishwary T. Shivgan, Yasunori Watanabe, Wanting He, Sean Callaghan, Ge Song, Peter Yong et al. · 2021 · Biochemistry
74. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2
    Ling Xu, 中国科学院昆明动物研究所，动物模型与人类疾病机理重点实验室，KIZ-CUHK生物资源与疾病分子机理联合实验室，云南 昆明 650223，中国, Dandan Yu, Yuhua Ma, Yulin Yao, Rong-Hua Luo, Xiao-Li Feng, Hourong Cai, Jian-Bao Han, Xuehui Wang et al. · 2020 · 动物学研究
75. SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
    Hyunjhung Jhun, Ho‐Young Park, Yasmin Hisham, Chang‐Seon Song, Soohyun Kim · 2021 · Immune Network
76. Developing a vaccine for covid-19
    Sarah Caddy · 2020 · BMJ
77. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
    Qingmei Jia, Helle Bielefeldt‐Ohmann, Rachel M. Maison, Saša Masleša-Galić, Sarah K. Cooper, Richard A. Bowen, Marcus A. Horwitz · 2021 · npj Vaccines
78. Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects
    Zhongbiao Fang, Jingting Lyu, Jianhua Li, Chaonan Li, Yuxuan Zhang, Yikai Guo, Ying Wang, Yanjun Zhang, Keda Chen · 2022 · Frontiers in Bioengineering and Biotechnology
79. SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters
    Zhiqi Song, Linlin Bao, Pin Yü, Feifei Qi, Shuran Gong, Jie Wang, Binbin Zhao, Mingya Liu, Yunlin Han, Wei Deng et al. · 2021 · Frontiers in Microbiology
80. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2
    Maopeng Wang, Tingting Fu, Jiayi Hao, Letian Li, Mingyao Tian, Ningyi Jin, Linzhu Ren, Chang Li · 2020 · International Journal of Biological Macromolecules
81. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population
    Zhigang Yi, Yun Ling, Xiaonan Zhang et al. · 2020 · Emerging Microbes & Infections
82. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
    Muhammad Umer Ashraf, Yeji Kim, Sunil Kumar, Dongyeob Seo, Maryam Ashraf, Yong‐Soo Bae · 2021 · Vaccines
83. Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
    Zhaoyong Zhang, Eric Zeng, Lu Zhang, Weiming Wang, Yingkang Jin, Jiye Sun, Shuxiang Huang, Wenguang Yin, Jun Dai, Zhen Zhuang et al. · 2021 · Cell Discovery
84. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates
    Zhao, Hui, Wang, Tie-Cheng, Li, Xiao-Feng, Zhang, Na-Na, Li, Liang, Zhou, Chao, Deng, Yong-Qiang, Cao, Tian-Shu, Yang, Guan, Li, Rui-Ting et al. · 2021 · Signal Transduction and Targeted Therapy
85. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
    Yongjun Sui, Yonas Bekele, Jay A. Berzofsky · 2021 · Pathogens
86. Graphene‐based Materials for Fighting Coronavirus Disease 2019: Challenges and Opportunities
    Imran Maqbool, Faisal Rehman, Faheeda Soomro, Zubeda Bhatti, Umeed Ali, Ashique Hussain Jatoi, Bhajan Lal, Muzaffar Iqbal, Shahnawaz Phulpoto, Akbar Ali et al. · 2021 · ChemBioEng Reviews
87. Expanding from materials to biology inspired by biomineralization
    Qi Wang, Lishan Hu, Xiaoyu Wang, Ruikang Tang · 2024 · Interdisciplinary materials
88. SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis
    Chitra Mohinder Singh Singal, Paritosh Jaiswal, Pankaj Seth · 2020 · ACS Chemical Neuroscience
89. SARS-CoV-2: vaccines in the pandemic era
    Dandan Li, Qihan Li · 2021 · Military Medical Research
90. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
    Yingying Du, Yu-Hua Xu, Jin Feng, Longbo Hu, Ya-Nan Zhang, Bo Zhang, Weili Guo, Runming Mai, Li-Yun Chen, Jianmin Fang et al. · 2021 · Vaccine
91. Single‐cell transcriptomic atlas reveals distinct immunological responses between COVID‐19 vaccine and natural SARS‐CoV‐2 infection
    Yi Wang, Xiaoxia Wang, Laurence Don Wai Luu, Jieqiong Li, Xiaodai Cui, Hailan Yao, Xin Zhang, Shaojin Chen, 付锦, Chongzhen Wang et al. · 2022 · Journal of Medical Virology
92. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
    Kizzmekia S. Corbett, Anne P. Werner, Sarah O’ Connell, Matthew Gagné, Lilin Lai, Juan I. Moliva, Barbara J. Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds et al. · 2021 · Nature Immunology
93. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
    Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
94. Is there a role for childhood vaccination against COVID‐19?
    Christiane Sigrid Eberhardt, Claire‐Anne Siegrist · 2020 · Pediatric Allergy and Immunology
95. Could live attenuated vaccines better control COVID-19?
    Shinya Okamura, Hirotaka Ebina · 2021 · Vaccine
96. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran
    Hamed Zare, Hadis Rezapour, Sara Mahmoudzadeh · 2021 · International Immunopharmacology
97. Vaccination and immunotherapies in neuroimmunological diseases
    Alexander Winkelmann, Micha Loebermann, Michael Harry Barnett, Hans‐Peter Hartung, Uwe Klaus Zettl · 2022 · Nature Reviews Neurology
98. Sensor array for rapid pathogens identification fabricated with peptide-conjugated 2D metal-organic framework nanosheets
    Zhaowei Sun, Shuai Wu, Ying Peng, Minghui Wang, Mohammed Jalalah, M.S. Al-Assiri, Farid A. Harraz, Jie An Yang, Genxi Li · 2020 · Chemical Engineering Journal
99. Animal coronaviruses and SARS‐CoV‐2
    Guangzhi Zhang, Bin Li, Dongwan Yoo, Tong Qin, Xiaodong Zhang, Yaxiong Jia, Shangjin Cui · 2020 · Transboundary and Emerging Diseases
100. Development of vaccines for SARS-CoV-2
     Wern Hann Ng, Xiang Liu, Suresh Mahalingam · 2020 · F1000Research